Published in AIDS Weekly, June 13th, 2005
"This has been a very busy and productive period," said CytRx President and CEO Steven A. Kriegsman. "Among our achievements, we completed a financing that supports our planned entry into phase II clinical trials with our lead compound arimoclomol. More recently, arimoclomol was granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis, also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.